Sean Whooley

PerkinElmer (NYSE:PKI) announced today that it launched its PKeye workflow monitor for remotely managing and monitoring workflows. Waltham, Massachusetts–based PerkinElmer’s cloud-based PKeye workflow monitor enables laboratory personnel to remotely handle PerkinElmer instruments and workflows in real-time through 24/7 access and visibility into laboratory operations. Get the full story at our sister site, MassDevice.

A life sciences real estate developer announced today that BD (NYSE:BDX) selected its property as a new facility for its biosciences business. Through a joint venture with Tishman Speyer and Bellco Capital, Breakthrough Properties confirmed that BD chose its Torrey View by Breakthrough property for an expanded San Diego reagent innovation center within its biosciences segment. Get…

Bruker (NSDQ:BRKR) announced today that it acquired Molecubes, a maker of benchtop preclinical nuclear molecular imaging (NMI) systems. Ghent, Belgium-based Bruker said in a news release that the acquisition, for which financial terms were not disclosed, will strengthen its position as a leading NMI solutions provider in preclinical and translational imaging research. The acquisitions will…

World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes. This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease. Some of those treatments involve insulin, which was discovered as a treatment for diabetes in…

Moderna (NSDQ:MRNA) shares took a big hit today on third-quarter results that came up short of the consensus forecast. MRNA shares were down 17.1% at $286.80 per share in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.2%. Get the full story at our…

Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) announced today that the U.S. bought 50 million more doses of its COVID-19 vaccine. The U.S. purchased the additional doses of the vaccine in its effort to support preparedness for pediatric vaccinations as it seeks authorization for use in younger adolescents and children. Earlier this month, Pfizer submitted a request…

DNA Script announced today that it raised $165 million in a Series C financing round, bringing its total capital raised to $280 million. South San Francisco-based DNA Script earmarked the funds raised to accelerate expansion and commercialization for the company’s Syntax benchtop nucleic acid printer and to broaden its portfolio of products powered by enzymatic…

Biogen (NSDQ:BIIB) shares ticked up today on third-quarter results that were mixed compared to the consensus forecast. The Cambridge, Massachusetts-based company posted profits of $329.2 million, or $2.22 per share, on sales of $2.2 billion for the three months ended Sept. 30, 2021, for a -53.1% bottom-line slide on a sales decline of -18%. Adjusted…

Pfizer (NYSE:PFE) and BioNTech (NSDQ: BNTX) announced today that they submitted a request to the FDA to expand the authorization of their COVID-19 vaccine to younger children. Expanded FDA emergency use authorization would allow for the use of the COVID-19 vaccine candidate, which has full FDA approval for people 16 years of age and older,…

Boehringer Ingelheim announced today that it acquired Abexxa Biologics, a developer of precision medicines for treating cancer. Acquiring Abexxa, which utilizes a new approach in immuno-oncology and oncology research, offers Boehringer Ingelheim access to the company’s expertise in targeting cancer-specific proteins located inside the cell instead of those expressed on the cell membrane, according to…

Johnson & Johnson’s Janssen Pharmaceutical Companies today announced a positive CHMP opinion on its Byannli schizophrenia treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued the positive opinion. The committee recommended using long-acting atypical antipsychotic Byannli (6-monthly paliperidone palmitate; PP6M) therapy for the maintenance treatment of schizophrenia. The recommendation…

AB Science today touted results from a study of masitinib in combination with docetaxel in treating prostate cancer. Paris-based AB Science presented the data at the 2021 American Urological Association (AUA) annual meeting, according to a news release. Masitinib in combination with docetaxel as a first-line treatment of metastatic castrate refractory prostate cancer (mCRPC) eligible…

FDA leaders have issued a statement regarding the agency’s plan for authorizing COVID-19 vaccines for children. The FDA plans to “follow the science” with eyes on COVID-19 vaccines for children younger than 12 as schools begin to get back in session around the country, the agency said in a news release attributed to acting Commissioner…

The National Institutes of Health (NIH) announced a plan to provide approximately $185 million over five years to a consortium researching genomic variation. Initiated and funded by NIH’s National Human Genome Research Institute (NHGRI), the Impact of Genomic Variation on Function (IGVF) consortium will receive the $185 million over five years in the form of…

The FDA’s relationship with Biogen is under scrutiny following the controversial approval granted to the company’s Aduhelm Alzheimer’s drug. According to a report from Endpoints News, the House Energy & Commerce and Oversight committee chairs issued a letter this week requesting that acting FDA Commissioner Dr. Janet Woodcock and the FDA provide very specific information by…

Johnson & Johnson (NYSE:JNJ) announced that it is accepting applications for its 2022 Women in STEM2D (WiSTEM2D) Scholars Award. New Brunswick, N.J.–based Johnson & Johnson’s award aims to support assistant or associate academic professors in the disciplines of science, technology, engineering, math, manufacturing and design through three years of mentorship from leaders at the company and…

Moderna (NSDQ:MRNA) announced that it initiated its submission to the FDA for a booster dose of its COVID-19 vaccine. Cambridge, Massachusetts–based Moderna expects to submit data to the European Medicines Agency and other regulatory authorities around the world in addition to the FDA in the coming days for the booster shot at a 50 µg…

Two senior vaccine leaders within the FDA are reportedly relinquishing their positions within the administration. According to a report from Endpoints News citing a letter released internally to FDA staff first reported on by BioCentury, Marion Gruber and Phil Krause will depart in the coming months due to frustrations over the delegation of certain decisions within…

Johnson & Johnson (NYSE:JNJ) today announced results from a trial of its HIV vaccine demonstrating a lack of sufficient protection against infection. New Brunswick, N.J.–based Johnson & Johnson’s Imbokodo Phase 2b HIV vaccine clinical trial found that the investigational vaccine regimen did not provide sufficient protection against HIV infection in a 2,600-person population of young…

Signal Rx Pharmaceuticals, Crystec and ADYA are working on a dry powder drug formulation for potentially treating COVID-19-related illness. The three companies’ collaboration for the dry powder formulation of SF2523 covers the treatment of pulmonary fibrosis, lung cancer and illnesses related to SARS-CoV-2, the virus causing COVID-19. Get the full story at our sister site,…

The FDA today issued approval for Pfizer and BioNTech’s COVID-19 vaccine, making it the first to receive full approval in the U.S. The approval covers the prevention of COVID-19 in individuals 16 years of age and older. The vaccine remains available under FDA emergency use authorization (EUA) for people who are 12 years of age…

Researchers at Purdue University and Houston Methodist Research Institute are touting a novel strategy for developing a tuberculosis (TB) vaccine. Bacillus Calmette-Guérin (BCG) is widely used as a vaccine against TB, but the researchers say it has a variable protection against neonatal and adult pulmonary TB, with protection ranging from 0% to 80% among infants.…

Reify Health, a company dedicated to shortening clinical trial timelines, announced today that it raised $220 million in a Series C financing round. Coatue Management led the round, with Iconiq Growth and Adams Street Partners joining along with existing investors Sierra Ventures and Battery Ventures. The round brings the company’s valuation to $2.2 billion, according…

Inovio Pharmaceuticals (NSDQ:INO) shares took a hit this morning on second-quarter results that missed the consensus forecast. INO shares were down more than –11% at $8.53 per share in morning trading today. Get the full story at our sister site, Drug Delivery Business News.

Merck (NYSE:MRK) announced today that it received FDA approval for Keytruda for treating high-risk, early-stage, triple-negative breast cancer (TNBC). Kenilworth, N.J.-based Merck’s Keytruda anti-PD-1 therapy received approval for use in combination with chemotherapy as neoadjuvant treatment, then continued as a single agent as adjuvant treatment after surgery, according to a news release. Approval was based…